Avid Bioservices Inc (CDMO)

[tarvacin]

biopharm,

Are you aware of Anti-TIM?

Does the immune system see tumors as foreign or self?
http://dx.doi.org/10.1146/annurev.immunol.21.120601.141135

Natural innate and adaptive immunity to cancer
http://dx.doi.org/10.1146/annurev-immunol-031210-101324

Cancer immunotherapy comes of age
http://dx.doi.org/10.1038/nature10673

Raising the bar: the curative potential of human cancer immunotherapy
http://dx.doi.org/10.1126/scitranslmed.3003634

Polarized immune responses differentially regulate cancer development
http://dx.doi.org/10.1111/j.1600-065X.2008.00600.x

Hallmarks of cancer: the next generation
http://dx.doi.org/10.1016/j.cell.2011.02.013

Immunity, inflammation, and cancer
http://dx.doi.org/10.1016/j.cell.2010.01.025

A cytokine-mediated link between innate immunity, inflammation, and cancer
http://dx.doi.org/10.1172/JCI31537

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion
http://dx.doi.org/10.1126/science.1203486

The three Es of cancer immunoediting
http://dx.doi.org/10.1146/annurev.immunol.22.012703.104803

Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
http://dx.doi.org/10.1038/nature01112

Coordinated regulation of myeloid cells by tumours
http://dx.doi.org/10.1038/nri3175

The blockade of immune checkpoints in cancer immunotherapy
http://dx.doi.org/10.1038/nrc3239

Immunosuppressive networks in the tumor environment and their therapeutic relevance
http://dx.doi.org/10.1038/nrc1586

Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
http://dx.doi.org/10.1038/nm863

B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma
http://dx.doi.org/10.1084/jem.20050930

Neutralizing tumor-promoting chronic inflammation: a magic bullet?
http://dx.doi.org/10.1126/science.1232227

Tumor promotion via injury- and death-induced inflammation
http://dx.doi.org/10.1016/j.immuni.2011.09.006

Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion
http://dx.doi.org/10.1084/jem.20090397

TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells
http://dx.doi.org/10.1016/j.stem.2010.11.014

TIM family of genes in immunity and tolerance
http://dx.doi.org/10.1016/S0065-2776(06)91006-2

Tim3 binding to galectin-9 stimulates antimicrobial immunity
http://dx.doi.org/10.1084/jem.20100687

Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1
http://dx.doi.org/10.1038/ni.2376

Immunostimulatory Tim-1-specific antibody deprograms Tregs and prevents transplant tolerance in mice
http://dx.doi.org/10.1172/JCI32562

T cell Ig and mucin 1 (TIM-1) is expressed on in vivo-activated T cells and provides a costimulatory signal for T cell activation
http://dx.doi.org/10.1073/pnas.0508643102

TIM-1 induces T cell activation and inhibits the development of peripheral tolerance
http://dx.doi.org/10.1038/ni1186

Anti-T-cell Ig and mucin domain-containing protein 1 antibody decreases TH2 airway inflammation in a mouse model of asthma
http://dx.doi.org/10.1016/j.jaci.2005.08.031

Tim-1 stimulation of dendritic cells regulates the balance between effector and regulatory T cells
http://dx.doi.org/10.1002/eji.201040993

TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells
http://dx.doi.org/10.1016/j.immuni.2007.11.011

TIM family proteins promote the lysosomal degradation of the nuclear receptor NUR77
http://dx.doi.org/10.1126/scisignal.2003200

The transcription factor NR4A1 (Nur77) controls bone marrow differentiation and the survival of Ly6C-monocytes
http://dx.doi.org/10.1038/ni.2063

NR4A1 (Nur77) deletion polarizes macrophages toward an inflammatory phenotype and increases atherosclerosis
http://dx.doi.org/10.1161/CIRCRESAHA.111.253377

Tim-2 regulates T helper type 2 responses and autoimmunity
http://dx.doi.org/10.1084/jem.20050308

Class IV semaphorin Sema4A enhances T-cell activation and interacts with Tim-2
10.1038/nature01037
http://dx.doi.org/10.1038/nature01037

Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis
http://dx.doi.org/10.1038/nature12428

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
http://dx.doi.org/10.1038/nm1093

CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice
http://dx.doi.org/10.1158/0008-5472.CAN-04-3104

De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent
http://dx.doi.org/10.1016/j.ccr.2005.04.014

Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease
http://dx.doi.org/10.1038/415536a

The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
http://dx.doi.org/10.1038/ni1271

Bat3 promotes T cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion
http://dx.doi.org/10.1038/nm.2871

Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection
http://dx.doi.org/10.1084/jem.20081398

Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells
http://dx.doi.org/10.1128/JVI.00639-09

Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma
http://dx.doi.org/10.1002/hep.25777

Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia
http://dx.doi.org/10.1182/blood-2010-10-310425

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients
http://dx.doi.org/10.1084/jem.20100637

TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression
http://dx.doi.org/10.1371/journal.pone.0030676

Putting the brakes on anticancer therapies: suppression of innate immune pathways by tumor-associated myeloid cells
http://dx.doi.org/10.1016/j.molmed.2013.06.001

Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity
http://dx.doi.org/10.1182/blood-2011-11-392951

Microenvironmental regulation of metastasis
http://dx.doi.org/10.1038/nrc2618

Identification of Tim4 as a phosphatidylserine receptor
http://dx.doi.org/10.1038/nature06307

Phosphatidylserine receptor Tim-4 is essential for the maintenance of the homeostatic state of resident peritoneal macrophages
http://dx.doi.org/10.1073/pnas.0910929107

T and B cell hyperactivity and autoimmunity associated with niche-specific defects in apoptotic body clearance in TIM-4-deficient mice
http://dx.doi.org/10.1073/pnas.0910359107

TIM-4, a receptor for phosphatidylserine, controls adaptive immunity by regulating the removal of antigen-specific T cells
http://dx.doi.org/10.4049/jimmunol.1001360

Milk fat globule epidermal growth factor-8 blockade triggers tumor destruction through coordinated cell-autonomous and immune-mediated mechanisms
http://dx.doi.org/10.1084/jem.20082614

Immunobiology of the TAM receptors
http://dx.doi.org/10.1038/nri2303

Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas
Cancer Immunol Immunother
http://dx.doi.org/10.1007/s00262-012-1371-9

Cell death in the neighborhood: direct microenvironmental effects of apoptosis in normal and neoplastic tissues
http://dx.doi.org/10.1002/path.2792

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
http://dx.doi.org/10.1084/jem.20100643

Anti-TIM3 antibody promotes T cell IFN-[ggr]-mediated antitumor immunity and suppresses established tumors Cancer Res
http://dx.doi.org/10.1158/0008-5472.CAN-11-0096

Expression of tumour-specific antigens underlies cancer immunoediting Nature
http://dx.doi.org/10.1038/nature10803

Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression Cancer Cell
http://dx.doi.org/10.1016/j.ccr.2010.11.011

Improved survival with ipilimumab in patients with metastatic melanoma
http://dx.doi.org/10.1056/NEJMoa1003466

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
http://dx.doi.org/10.1056/NEJMoa1200690